A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

Starting soon · Phase 2

Conditions studied: HCC - Hepatocellular Carcinoma

In brief

This is a Phase 2, open-label, multicenter,study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant - Page 1 of 5 - protein) combine with IMM27M(Anti-CTLA-4 Humanized monoclonal antibody) in patients with advanced hepatocellular carcinoma who not have received the treatment for aHCC in past

Key facts

Study ID

NCT07687914

Run by

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

People needed

50

Starts

2026-07-23

Expected to finish

2028-07-23

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has provided informed consent prior to initiation of any study specific activities/procedures.
• Age greater than or equal to 18 years old and ≤ 75 years old at the same time of signing the informed consent.
• Histologically or cytologically confirmed for HCC
• Eastern Cooperative Oncology Group (ECOG) 0 to 1.
• Adequate organ function as defined in protocol.

You may not qualify if…

• History of other malignancy within the past 5 years with exceptions.
• Systemic chemotherapy was administered within 4 weeks prior to the first administration.
• Activated symptomatic brain metastases and leptomeningeal disease.
• History of hepatic encephalopathy disease in past 12 months.
• Participants with symptoms and/or clinical signs and/or uncontrolled active systemic infection within 14 days prior to the first dose of study treatment. Participant has known active infection requiring parenteral antibiotic treatment.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.